The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Peeters on the Frequency of S492R Mutations Following EGFR Inhibition in mCRC
June 27th 2014Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the frequency of S492R mutations found in patients with metastatic colorectal cancer patients who were treated with panitumumab or cetuximab monotherapy.
Dr. Tabernero on Sequencing Angiogenesis Inhibitors in mCRC
June 27th 2014Josep Tabernero, MD, PhD, head, Medical Oncology Department, Vall d'Hebron University Hospital, director, Vall d'Hebron Institute of Oncology, discusses his opinions on which patients with metastatic colorectal cancer should receive aflibercept following bevacizumab.
Ruxolitinib Combo Improves Outcomes in Metastatic Pancreatic Cancer
June 26th 2014Adding ruxolitinib to capecitabine as a second-line treatment for patients with metastatic pancreatic cancer significantly improved survival for a subgroup with a high degree of local and systemic inflammation compared with capecitabine plus placebo.
Dr. O'Reilly on Nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX in Pancreatic Cancer
June 25th 2014Eileen M. O'Reilly, MD, associate director, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, discusses using nab-paclitaxel plus gemcitabine versus FOLFIRINOX as treatment for patients with untreated metastatic pancreatic cancer.
Necitumumab Delivers Rare Survival Benefit in Squamous NSCLC
Adding necitumumab to standard of care with gemcitabine-cisplatin significantly improves survival compared with chemotherapy alone as first-line treatment in patients with stage IV non–small-cell lung cancer of squamous histology.
Dr. Younes on R-CHOP in Combination with Ibrutinib in DLBCL
June 3rd 2014Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses a phase III study of ibrutinib in combination R-CHOP in patients with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma.
Anti-CD38 Antibody Generates Excitement in Multiple Myeloma
The CD38-specific monoclonal antibody SAR650984 demonstrated encouraging efficacy as a monotherapy and in combination with dexamethasone and lenalidomide without reaching a maximum tolerated dose in patients with heavily pretreated multiple myeloma.
'Smart' Alkylator TH-302 Shows Clinical Benefit in Early Multiple Myeloma Trial
June 2nd 2014The addition of the investigational hypoxia-targeted drug TH-302 to dexamethasone has demonstrated beneficial activity and a manageable adverse event profile in the treatment of patients with relapsed/refractory multiple myeloma.
Practice-Changing Data Revealed for Premenopausal HR+ Breast Cancer
A joint analysis of two phase III trials involving a total of 4690 premenopausal women with hormone-receptor–positive (HR+) breast cancer demonstrated that adjuvant use of the aromatase inhibitor (AI), exemestane, reduced relative risk of developing subsequent invasive cancer by 28% compared with tamoxifen when both agents were combined with ovarian function suppression (OFS).
HPV-Targeting Immunotherapy Shows Early Promise in Cervical Cancer
June 2nd 2014Two patients with metastatic cervical cancer achieved durable complete responses that have so far lasted from 15 to 22 months through an adoptive T-cell therapy (ACT) targeting the human papillomavirus (HPV) in a study that researchers say supports the concept that the experimental immunotherapy approach may be beneficial in a variety of tumor types.
New Study Findings Confirm Pembrolizumab's Durable Responses in Metastatic Melanoma
June 2nd 2014The anti-PD 1 checkpoint inhibitor, pembrolizumab, continues to deliver impressive results in patients with advanced melanoma-producing long-lasting responses and improved overall survival, regardless of whether patients have been previously treated with ipilimumab.
Dr. Fong Discusses Intratumoral Electroporation of Plasmid IL-12 in Melanoma
June 2nd 2014Lawrence Fong, MD, from the University of California, San Francisco, discusses the systemic antitumor effect and clinical response in a phase II trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma.